DCAL
Dishman Carbogen Amcis Limited (DCAL) Stock Analysis
Dishman Carbogen Amcis Limited is an Indian contract research and manufacturing organisation for pharma. It produces APIs and intermediates for global innovators from facilities in India and Europe. CDMO demand and complex chemistry capabilities support its business. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Biotechnology
₹149.70
-0.45% 1W | -50.10% 52W
Market Cap
2.3k CR
P/E Ratio
145.3
52W High
₹303
52W Low
₹128.5
Div. Yield
0%
Beta
0.7
50 DMA
₹172.9
200 DMA
₹184.9
Profit Margin
0.6%
Inst. Own.
2.7%
✅ BOUNCE FROM SUPPORT
✅ BOUNCE FROM SUPPORT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 723 | 587 | 651 | 655 | 524 | 789 | 682 | 716 | 708 | 653 | 720 | 851 | 678 |
| Expenses | 602 | 526 | 610 | 592 | 495 | 642 | 542 | 564 | 567 | 504 | 607 | 688 | 618 |
| Operating Profit | 122 | 61 | 41 | 63 | 29 | 147 | 140 | 153 | 141 | 149 | 113 | 163 | 60 |
| OPM % | 17% | 10% | 6% | 10% | 6% | 19% | 21% | 21% | 20% | 23% | 16% | 19% | 9% |
| Other Income | 7 | 5 | 6 | 4 | -4 | 4 | 8 | -4 | 22 | 8 | 7 | 15 | 16 |
| Interest | 28 | 27 | 33 | 31 | 32 | 37 | 49 | 42 | 43 | 42 | 46 | 43 | 37 |
| Depreciation | 70 | 75 | 80 | 85 | 71 | 72 | 72 | 79 | 81 | 84 | 84 | 89 | 91 |
| Profit before tax | 29 | -36 | -66 | -49 | -78 | 42 | 27 | 28 | 39 | 31 | -10 | 46 | -51 |
| Tax % | 42% | 13% | -10% | 42% | 0% | 21% | 83% | -56% | 39% | -114% | 24% | 53% | 13% |
| Net Profit | 17 | -41 | -60 | -70 | -78 | 33 | 5 | 43 | 23 | 65 | -13 | 22 | -58 |
| EPS in Rs | 1.08 | -2.61 | -3.80 | -4.46 | -4.95 | 2.11 | 0.30 | 2.75 | 1.49 | 4.16 | -0.83 | 1.39 | -3.69 |
| Metric | Mar 2011 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,031 | 1,714 | 1,695 | 2,059 | 2,044 | 1,912 | 2,141 | 2,413 | 2,616 | 2,712 | 2,932 | 2,901 |
| Expenses | 830 | 1,261 | 1,249 | 1,507 | 1,540 | 1,638 | 1,809 | 2,081 | 2,329 | 2,243 | 2,366 | 2,416 |
| Operating Profit | 201 | 452 | 445 | 552 | 503 | 274 | 331 | 332 | 286 | 469 | 566 | 485 |
| OPM % | 20% | 26% | 26% | 27% | 25% | 14% | 15% | 14% | 11% | 17% | 19% | 17% |
| Other Income | 14 | 26 | 46 | 54 | 39 | 16 | 29 | -20 | 22 | 4 | 52 | 47 |
| Interest | 56 | 49 | 49 | 57 | 62 | 48 | 57 | 86 | 120 | 159 | 174 | 169 |
| Depreciation | 69 | 214 | 211 | 240 | 283 | 308 | 308 | 281 | 311 | 294 | 339 | 348 |
| Profit before tax | 91 | 216 | 231 | 309 | 197 | -65 | -4 | -55 | -122 | 19 | 105 | 15 |
| Tax % | 12% | 33% | 33% | 32% | 20% | 154% | -524% | -45% | 26% | 83% | 7% | |
| Net Profit | 80 | 145 | 155 | 210 | 159 | -165 | 18 | -30 | -153 | 3 | 97 | 16 |
| EPS in Rs | 9.58 | 13.03 | 10.10 | -10.53 | 1.15 | -1.90 | -9.79 | 0.21 | 6.22 | 1.03 | ||
| Dividend Payout % | 0% | 0% | 0% | 2% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 9.0% | – |
| Profit CAGR | 140.0% | 21.0% | – |
Shareholding Pattern
Promoters59.32%
FIIs9.94%
DIIs1.27%
Public29.48%
Promoters59.32%
FIIs8.07%
DIIs1.37%
Public31.23%
Promoters59.32%
FIIs7.66%
DIIs1.27%
Public31.75%
Promoters59.32%
FIIs7.45%
DIIs1.63%
Public31.60%
Promoters59.32%
FIIs6.86%
DIIs2.06%
Public31.76%
Promoters59.32%
FIIs9.34%
DIIs2.55%
Public28.79%
Promoters59.32%
FIIs8.70%
DIIs2.36%
Public29.63%
Promoters59.32%
FIIs9.49%
DIIs1.26%
Public29.94%
Promoters59.32%
FIIs7.45%
DIIs1.63%
Public31.60%
Promoters59.32%
FIIs6.86%
DIIs2.06%
Public31.76%
DCAL
Holdings Analysis
Key strengths & risk signals
55
Overall
52
Fundamental
59
Technical
Risks (4)
OVERVALUED! PEG of 6.92 means expensive relative to growth rate.
POOR YEAR! Stock declined 50.1% in the last year.
WEAK POSITION! Current price (149.7) is below both moving averages.
WEAK! Trading at 12.1% of 52W range - near yearly lows.
Strengths (3)
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 11 up days, 18 down days. Avg volume on up days: 292,826 vs down days: 212,589. Ratio: 1.38x
TESTING SUPPORT! Stock is at key support level.
Fundamental & Technical Analysis
55Overall
52Fundamental
59Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 9.0% (MODERATE, 8/15). Profit CAGR: 21.0% (EXCELLENT, 15/15).
Profit Margin
2/10
LOW MARGIN! 0.6% profit margin - thin profits.
PEG Valuation
0/10
OVERVALUED! PEG of 6.92 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
8/10
LOW DEBT! D/E of 0.41 - strong balance sheet.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 28.65% public ownership - balanced ownership structure.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (172.9) is below 200-day average (184.9) - negative signal.
Price Position
2/10
WEAK POSITION! Current price (149.7) is below both moving averages.
Trend Pattern
16/20
TESTING SUPPORT! Stock is at key support level.
52W Performance
0/10
POOR YEAR! Stock declined 50.1% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 11 up days, 18 down days. Avg volume on up days: 292,826 vs down days: 212,589. Ratio: 1.38x
RSI
4/5
APPROACHING OVERSOLD! RSI at 32.9 - watch for reversal.
52W Range
1/5
WEAK! Trading at 12.1% of 52W range - near yearly lows.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 0.5% (1 week), 12.3% (1 month), 23.6% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.70 - stable stock, less market risk.
DCAL
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-05-25 | Concall PDF | |
| Q3FY262026-02-10 | Concall PDF | |
| Q2FY262025-11-11 | Concall PDF |
Peer Comparison
Healthcare · Biotechnology · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DCAL | ₹149.70 | 145.3 | 0.6% | 9.0% | 21.0% | -50.1% | 55 | BOUNCE FROM SUPPORT | -347.9% | -367.3% | -4.2% | -20.4% |
| PANACEABIO | ₹345.20 | – | -1.1% | 10.1% | – | -17.9% | 49 | BOUNCE FROM SUPPORT | -42.5% | +360.0% | +19.7% | +19.7% |
| HALEOSLABS | ₹1,563.70 | 29.9 | 4.9% | 0.3% | 14.7% | +41.6% | 69 | BREAKOUT | -38.1% | +550.0% | -11.6% | -2.9% |
| LYKALABS | ₹72.70 | – | -6.6% | 13.3% | – | -21.3% | 50 | BREAKDOWN | +133.3% | -127.6% | +28.2% | +51.1% |
| ZOTA | ₹1,324.10 | – | -17.0% | 56.7% | – | -7.9% | 57 | CONSOLIDATING UP | +204.9% | +207.0% | +67.6% | +6.4% |
| 3BBLACKBIO | ₹1,586.40 | 24.1 | 36.3% | 31.9% | 32.2% | +40.7% | 76 | CONSOLIDATING UP | -24.6% | -1.0% | +50.9% | -5.4% |
| SUPRIYA | ₹847.60 | 34.4 | 22.7% | 21.2% | 32.5% | +23.4% | 83 | BOUNCE FROM SUPPORT | -31.0% | -67.7% | +30.7% | -31.4% |
| BLUEJET | ₹514.60 | 38 | 26.5% | 9.4% | 15.7% | -17.2% | 73 | BOUNCE FROM SUPPORT | -14.1% | +21.8% | -17.4% | +24.9% |
Data from TradeAlone · Updated daily
DCAL News
Dishman Carbogen Amcis Limited (dcal) Q1fy27: Net Revenue Dips, CDMO Segment Struggles2026-08-17Dishman Carbogen Amcis Limited DCAL: Carbogen AMCIS AG Commissions 1,200 Kwp Solar Power Plant2026-06-29Dishman Carbogen Amcis Limited (dcal) Q4fy26: Revenue Surges 18.9%, PAT Up 446%2026-05-20Dcal Subsidiary Achieves Successful Gmp Inspection in China2026-05-05
